Found: 9
Select item for more details and to access through your institution.
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1201, doi. 10.1007/s40273-021-01088-5
- By:
- Publication type:
- Article
The Challenges of Measuring Informal Care Time: A Review of the Literature.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1209, doi. 10.1007/s40273-021-01053-2
- By:
- Publication type:
- Article
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1225, doi. 10.1007/s40273-021-01072-z
- By:
- Publication type:
- Article
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1243, doi. 10.1007/s40273-021-01065-y
- By:
- Publication type:
- Article
A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1271, doi. 10.1007/s40273-021-01071-0
- By:
- Publication type:
- Article
EQ-5D-Y Population Norms for Japanese Children and Adolescents.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1299, doi. 10.1007/s40273-021-01063-0
- By:
- Publication type:
- Article
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1309, doi. 10.1007/s40273-021-01068-9
- By:
- Publication type:
- Article
Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1327, doi. 10.1007/s40273-021-01064-z
- By:
- Publication type:
- Article
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 11, p. 1343, doi. 10.1007/s40273-021-01091-w
- By:
- Publication type:
- Article